biostudies-literatureYebyo HGIntramural NIH HHSNCATS NIH HHSNIDA NIH HHSNIA NIH HHSNCRR NIH HHSNIAID NIH HHSNHLBI NIH HHSNIMH NIH HHSNIAAA NIH HHSSwiss National Science FoundationNEI NIH HHSNIMHD NIH HHSNCI NIH HHSe001132https://www.ebi.ac.uk/biostudies/studies/S-EPMC12090529biostudies-literatureUnknown4(1)<h4>Objective</h4>To evaluate the effectiveness and benefit-harm balance of various statins for the primary prevention of cardiovascular disease in people with HIV.<h4>Design</h4>Target trial and modelling study.<h4>Setting</h4>North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), 1995 to 2019. NA-ACCORD integrates individual level data from >20 HIV cohorts across the US and Canada from people with HIV who have successfully linked into care.<h4>Participants</h4>157 699 people with HIV enrolled in one of the cohorts of NA-ACCORD. 54 165 eligible individuals, aged 40-75 years, were enrolled in the target trial.<h4>Main outcome measures</h4>The primary outcomes for the target trial were the 10 year effects of statins on cardiovascular disease events (fatal and non-fatalBMJ medicineStatins for primary prevention of cardiovascular events in people with HIV: target trial and modelling study.PMC12090529K01 AI131895K24 DA000432U01 AI038858U01 HL146205U01 HL146204KL2 TR000421U01 AI038855U01 HL146203U01 HL146208R01 DA011602U01 AI068636R01 AA016893U01 HL146242U01 HL146241U01 AA020790U01 HL146240N02 CP055504U01 HL146202U01 HL146245U01 HL146201UL1 TR000083U01 AI068634K23 EY013707U10 EY008067P30 AI027767P30 AI027763P30 AI036219F31 AI124794UL1 TR000004U24 AA020794194504U01 HL146194U01 HL146193U01 HL146192P30 AI050410K01 AI093197U10 EY008057P30 AI027757U01 AA013566P30 AI110527F31 DA037788U10 EY008052G12 MD007583UL1 RR024131P30 AI094189R24 AI067039U01 DA036935K24 AI065298R01 AG053100N01 CP001004P30 MH062246R01 DA012568P30 AI050409U01 HL146333U01 AI069918U54 MD007587Z01 CP010176U01 AI069432K24 AI118591U01 AI069434Guenthard HFRehfuess EASenn OLoutfy MSterling TRYebyo HGSerra NHaile SRLangselius ONapravnik SThorne JEMarconi VCLucas GMBurkholder GAAlthoff KNKarris MCoburn SBLang RPuhan MASilverberg MJColasanti JAfalseStatins for primary prevention of cardiovascular events in people with HIV: target trial and modelling study.<h4>Objective</h4>To evaluate the effectiveness and benefit-harm balance of various statins for the primary prevention of cardiovascular disease in people with HIV.<h4>Design</h4>Target trial and modelling study.<h4>Setting</h4>North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), 1995 to 2019. NA-ACCORD integrates individual level data from >20 HIV cohorts across the US and Canada from people with HIV who have successfully linked into care.<h4>Participants</h4>157 699 people with HIV enrolled in one of the cohorts of NA-ACCORD. 54 165 eligible individuals, aged 40-75 years, were enrolled in the target trial.<h4>Main outcome measures</h4>The primary outcomes for the target trial were the 10 year effects of statins on cardiovascular disease events (fatal and non-fatal2025-01-01T00:00:00Z20252026-03-27T16:44:41.874Z2025-08-31T03:04:48.215ZS-EPMC120905294039564910.1136/bmjmed-2024-001132